OBJECTIVE: To characterize the cervical cancers diagnosed following a Pap-negative, high risk human papillomavirus (HPV)-positive (Pap-/HPV+) screen in routine clinical practice. METHODS: Using data from Kaiser Permanente Northern California, we investigated the cases of cervical cancer diagnosed between January, 2003 and January, 2009 following Pap-/HPV+ screen. Two cervical specimens were routinely collected for cervical cancer screening, one for conventional cytology and the other for high risk HPV testing using Hybrid Capture 2 (Qiagen). RESULTS: Forty-four women (median age at diagnosis=44years) were diagnosed with primary invasive cervical cancer with a recent history of one or more Pap-/HPV+ screens. Twenty-six women had one Pap-/HPV+ screen preceding the diagnosis of cancer, 15 had two, and three had three. There were 16 squamous cancers, one small cell cancer, 24 adenocarcinomas, 2 adenosquamous carcinomas, and one case with separate invasive squamous and adenocarcinoma. FIGO Stage was IA in 11 women, IB in 31 women and IIA in 2 women. Treatment included a pelvic node dissection in 30, 2 (6.7%) of whom had positive nodes. CONCLUSIONS: HPV testing contributes to early cervical cancer diagnosis detection in women with negative Pap tests. Most women in this cohort have early stage, node negative, treatable and potentially curable disease. Adenocarcinoma predominated as might be expected because cytology misses these cancers and their precursors. The majority of cancers were diagnosed following a single Pap-/HPV+ screen, suggesting that effective triage to colposcopy of women with a Pap-/HPV+ screen would be preferable to retesting in one year as currently recommended.
OBJECTIVE: To characterize the cervical cancers diagnosed following a Pap-negative, high risk human papillomavirus (HPV)-positive (Pap-/HPV+) screen in routine clinical practice. METHODS: Using data from Kaiser Permanente Northern California, we investigated the cases of cervical cancer diagnosed between January, 2003 and January, 2009 following Pap-/HPV+ screen. Two cervical specimens were routinely collected for cervical cancer screening, one for conventional cytology and the other for high risk HPV testing using Hybrid Capture 2 (Qiagen). RESULTS: Forty-four women (median age at diagnosis=44years) were diagnosed with primary invasive cervical cancer with a recent history of one or more Pap-/HPV+ screens. Twenty-six women had one Pap-/HPV+ screen preceding the diagnosis of cancer, 15 had two, and three had three. There were 16 squamous cancers, one small cell cancer, 24 adenocarcinomas, 2 adenosquamous carcinomas, and one case with separate invasive squamous and adenocarcinoma. FIGO Stage was IA in 11 women, IB in 31 women and IIA in 2 women. Treatment included a pelvic node dissection in 30, 2 (6.7%) of whom had positive nodes. CONCLUSIONS:HPV testing contributes to early cervical cancer diagnosis detection in women with negative Pap tests. Most women in this cohort have early stage, node negative, treatable and potentially curable disease. Adenocarcinoma predominated as might be expected because cytology misses these cancers and their precursors. The majority of cancers were diagnosed following a single Pap-/HPV+ screen, suggesting that effective triage to colposcopy of women with a Pap-/HPV+ screen would be preferable to retesting in one year as currently recommended.
Authors: Xavier Castellsagué; Mireia Díaz; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Rosanna W Peeling; Rhoda Ashley; Jennifer S Smith; Peter J F Snijders; Chris J L M Meijer; F Xavier Bosch Journal: J Natl Cancer Inst Date: 2006-03-01 Impact factor: 13.506
Authors: Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford Journal: Int J Cancer Date: 2007-08-01 Impact factor: 7.396
Authors: Marc Arbyn; Peter Sasieni; Chris J L M Meijer; Christine Clavel; George Koliopoulos; Joakim Dillner Journal: Vaccine Date: 2006-08-31 Impact factor: 3.641
Authors: Jack Cuzick; Christine Clavel; Karl-Ulrich Petry; Chris J L M Meijer; Heike Hoyer; Samuel Ratnam; Anne Szarewski; Philippe Birembaut; Shalini Kulasingam; Peter Sasieni; Thomas Iftner Journal: Int J Cancer Date: 2006-09-01 Impact factor: 7.396
Authors: Sok Cheon Pak; Martje Martens; Ruud Bekkers; Alex J Crandon; Russell Land; James L Nicklin; Lewis C Perrin; Andreas Obermair Journal: Aust N Z J Obstet Gynaecol Date: 2007-12 Impact factor: 2.100
Authors: Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner Journal: N Engl J Med Date: 2007-10-18 Impact factor: 91.245
Authors: Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco Journal: N Engl J Med Date: 2007-10-18 Impact factor: 91.245
Authors: Guglielmo Ronco; Jack Cuzick; Paola Pierotti; Maria Paola Cariaggi; Paolo Dalla Palma; Carlo Naldoni; Bruno Ghiringhello; Paolo Giorgi-Rossi; Daria Minucci; Franca Parisio; Ada Pojer; Maria Luisa Schiboni; Catia Sintoni; Manuel Zorzi; Nereo Segnan; Massimo Confortini Journal: BMJ Date: 2007-05-21
Authors: Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney Journal: J Low Genit Tract Dis Date: 2013-04 Impact factor: 1.925
Authors: Lea A Moukarzel; Ana M Angarita; Christopher VandenBussche; Anne Rositch; Carol B Thompson; Amanda N Fader; Kimberly Levinson Journal: J Low Genit Tract Dis Date: 2017-04 Impact factor: 1.925
Authors: Rong Wang; Robert W van Leeuwen; Aniek Boers; Harry G Klip; Tim de Meyer; Renske D M Steenbergen; Wim van Criekinge; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman Journal: Oncotarget Date: 2016-12-06
Authors: Rachel D Conrad; Angela H Liu; Nicolas Wentzensen; Roy R Zhang; S Terence Dunn; Sophia S Wang; Mark Schiffman; Michael A Gold; Joan L Walker; Rosemary E Zuna Journal: Cancer Cytopathol Date: 2018-10-23 Impact factor: 5.284